Do not stop or change your medication without speaking to a pharmacist or healthcare professional.

Canada Drug Shortages in October 2026: What Started and What Ended

Published November 18, 2026 · Updated November 18, 2026 · 9 min read

Quick answer

In October 2026, 142 drug products in Canada went into shortage. Most were generic medications for blood pressure, epilepsy and nerve pain, mental health, and infections, and Apotex, Sandoz, and JAMP filed the most reports. In the same month, 160 shortages were resolved, including Synthroid, Creon, Tyenne, and several ADHD medications. About 7 in 10 new shortages were caused by manufacturing disruptions. The only new Tier 3 shortages were three Estradot estrogen patch strengths. Two of those were resolved by early November, and Estradot 75 was still short.

October 2026 at a glance

This is a recap of every Health Canada drug shortage report that started or ended in October 2026, based on the reports manufacturers filed with Drug Shortages Canada. Statuses are as of November 18, 2026. Click any product to see its live status today.

  • 142 products went into shortage (shortage start date in October). By mid-November, 99 were still in active shortage and 43 had already been resolved again.
  • 160 shortages were resolved (shortage end date in October). The median resolved shortage had lasted about 7 weeks, but 22 of them had lasted more than a year.
  • Three new Tier 3 shortages, all estrogen patches: Sandoz's Estradot 25, 37.5, and 75 mcg went short on October 13. The 25 and 37.5 mcg patches were back by early November, but Estradot 75 mcg was still short, with an estimated end date of December 18, 2026. Tier 3 is Health Canada's highest-impact rating. See what Tier 3 means.
  • Manufacturing problems drove most of it. 98 of the 142 new shortages cited a disruption in manufacturing. Another 22 cited increased demand, and 12 cited shipping delays.
  • Generic makers dominated again. Apotex filed 33 of the new shortage reports, followed by Sandoz (15) and JAMP (11).

Notable new shortages

  • Tamiflu for children: Tamiflu oral suspension went short on October 23 because of higher demand, right at the start of flu season. Its estimated end date is December 1. Tamiflu capsules and generic oseltamivir aren't part of this report. See the cold and flu medication guide.
  • A very long estimate for losartan: Jamp-Losartan 50 mg and 100 mg list an estimated end date of December 31, 2030. A date that far out usually means the company doesn't know when supply will return. Many other companies make losartan, so ask your pharmacist about another brand.
  • Epilepsy and nerve pain: Apo-Gabapentin 100, 300, and 400 mg, Apo-Levetiracetam 250, 500, and 750 mg, Apo-Brivaracetam 50 mg, and Taro-Pregabalin 25 mg. Don't stop a seizure medication suddenly. Ask your pharmacist for another manufacturer's version instead.
  • Mental health: Zoloft 25 mg, Apo-Duloxetine 30 and 60 mg, Apo-Citalopram 40 mg, Jamp Venlafaxine XR 37.5 mg, Luvox 50 mg, Zeldox 20 and 40 mg, and Teva-Haloperidol 1 and 2 mg. See why psychiatric medications keep going short.
  • Stomach-acid medications: Tecta 40 mg went short again only three weeks after its last shortage ended. Sanis Rabeprazole EC 10 mg and Apo-Lansoprazole 15 mg also went short. See the Tecta guide and the rabeprazole guide.
  • Minoxidil: Loniten 10 mg went short again because of demand, with an estimated end date of January 29, 2027. See the minoxidil guide.
  • Acetaminophen and antifungals: Apo-Acetaminophen Extra Strength 500 mg, Novo-Gesic 325 mg and Forte 500 mg, and three fluconazole products, including Diflucan 50 mg. Other acetaminophen brands are still widely available.
  • Hospital and cancer drugs: vancomycin injection (Hikma), daptomycin injection (Sandoz), methotrexate injection (PMS), and Sandoz sunitinib 12.5, 25, and 50 mg.

Notable shortages that ended

  • Long-running shortages finally over: Teva-Mirtazapine 30 mg (about 3 years), ACH-Alendronate 10 mg (about 2.5 years), Apo-Pregabalin 75 mg (over 2 years), and Teva-Atomoxetine 10 mg, Sivem tenofovir 300 mg, and PMS-Sitagliptin 50 mg (each over a year).
  • Thyroid: Synthroid 50, 75, 88, and 100 mcg were all back by early November.
  • Pancreatic enzymes: Creon Minimicrospheres 10 and 25 were resolved in October, and Creon 35 followed in November. See the Creon and Cotazym guide.
  • ADHD: Dexedrine Spansule 10 mg, Teva-Dextroamphetamine SR 15 mg, Jornay PM 20 mg, and Apo-Amphetamine XR 5 and 30 mg. See the ADHD medication guide.
  • Blood thinners: Apo-Clopidogrel 75 and 300 mg, Apo-Dabigatran 110 and 150 mg, Apo-Rivaroxaban 15 mg, and Teva-Rivaroxaban 20 mg.
  • Others: Tyenne (tocilizumab) 80, 200, and 400 mg, Metadol 1 and 10 mg, and five olanzapine products from Sandoz and Pharmascience.

“Resolved” means the manufacturer has told Health Canada supply is back. Pharmacies can take a few days to a few weeks to restock, so if your pharmacy still can't fill a resolved product, ask them to order it from their wholesaler.

Discontinued in October

These products were permanently discontinued in October. They won't come back, so your prescriber or pharmacist will need to move you to an alternative (shortage vs. discontinued):

Just after October ended, Pfizer also permanently discontinued Premarin Vaginal Cream in Canada, and it is ending sales of Premarin tablets.

Full list: products that went into shortage

Sorted by active ingredient. Products with no note were still in active shortage on November 18.

Full list: shortages resolved

Each entry shows how long that shortage lasted, from its reported start date to its end date.

If your medication is on the list

A shortage usually affects one manufacturer's product at one strength. Other brands of the same drug are often still available. Ask your pharmacist whether they can switch you to another manufacturer, and read what to do when your medication is in shortage. To get an email when a product's status changes, open its page on MedShort and use “Notify me”.

Related Guides

Latest Canadian Shortage Updates

BGP PHARMA ULC

25MG · DIN 02323052

Active Shortage

Updated: 2026-11-19

SANIS HEALTH INC

240MG · DIN 02400456

Active Shortage

Updated: 2026-11-18

KNIGHT THERAPEUTICS INC.

3MG · DIN 02398257

Active Shortage

Updated: 2026-11-18

PHARMASCIENCE INC

0.5% · DIN 02432218

Active Shortage

Updated: 2026-11-18

Guide last reviewed November 18, 2026. MedShort.ca is an independent tracking tool and does not provide medical advice.